L
Lars Bullinger
Researcher at Charité
Publications - 451
Citations - 33200
Lars Bullinger is an academic researcher from Charité. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 75, co-authored 373 publications receiving 27820 citations. Previous affiliations of Lars Bullinger include Stanford University & University of Ulm.
Papers
More filters
Journal ArticleDOI
Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia
Hartmut Döhner,Stephan Stilgenbauer,Axel Benner,Elke Leupolt,Alexander Kröber,Lars Bullinger,Konstanze Döhner,Martin Bentz,Peter Lichter +8 more
TL;DR: Genomic aberrations in chronic lymphocytic leukemia are important independent predictors of disease progression and survival and have implications for the design of risk-adapted treatment strategies.
Journal ArticleDOI
Genomic Classification and Prognosis in Acute Myeloid Leukemia
Elli Papaemmanuil,Moritz Gerstung,Lars Bullinger,Verena I. Gaidzik,Peter Paschka,Nicola D. Roberts,Nicola E. Potter,Michael Heuser,Felicitas Thol,Niccolo Bolli,Gunes Gundem,Peter Van Loo,Inigo Martincorena,Peter Ganly,Laura Mudie,Stuart McLaren,Sarah O’Meara,Keiran Raine,David R. Jones,Jon W. Teague,Adam Butler,Mel Greaves,Arnold Ganser,Konstanze Döhner,Richard F. Schlenk,Hartmut Döhner,Peter J. Campbell +26 more
TL;DR: The driver landscape in AML reveals distinct molecular subgroups that reflect discrete paths in the evolution of AML, informing disease classification and prognostic stratification.
Journal ArticleDOI
Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia
Richard F. Schlenk,Konstanze Döhner,Jürgen Krauter,Stefan Fröhling,Andrea Corbacioglu,Lars Bullinger,Marianne Habdank,Daniela Späth,Michael Morgan,Axel Benner,Brigitte Schlegelberger,Gerhard Heil,Arnold Ganser,Hartmut Döhner +13 more
TL;DR: Genotypes defined by the mutational status of NPM1, FLT3, CEBPA, MLL, and MLL are associated with the outcome of treatment for patients with cytogenetically normal AML.
Journal ArticleDOI
Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia.
Lars Bullinger,Konstanze Döhner,Eric Bair,Stefan Fröhling,Richard F. Schlenk,Robert Tibshirani,Hartmut Döhner,Jonathan R. Pollack +7 more
TL;DR: The use of gene-expression profiling improves the molecular classification of adult AML and identifies new molecular subtypes of AML, including two prognostically relevant subgroups in AML with a normal karyotype.
Journal ArticleDOI
Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.
Konstanze Döhner,Richard F. Schlenk,Marianne Habdank,Claudia Scholl,F.G. Rücker,Andrea Corbacioglu,Lars Bullinger,Stefan Fröhling,Hartmut Döhner +8 more
TL;DR: NPM1 mutations in the absence of FLT3 ITD define a distinct molecular and prognostic subclass of young-adult AML patients with normal cytogenetics, and is associated with specific clinical, phenotypical, and genetic features.